Skip to search formSkip to main contentSkip to account menu

Carboplatin

Known as: CBDCA, cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II), (SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum 
A second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two… 
National Institutes of Health

Related topics

Related topics

44 relations

Broader (2)

Antineoplastic AgentsCisplatin

Narrower (12)

BIC protocolCIV protocolCarbo-MVE protocolDWA 2114
CAC protocolCTCb regimenCarboplatin 10 MG/ML Injectable SolutionCarboplatin/Neovastat/Paclitaxel

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Review
2014
Review
2014
Cisplatin in cancer therapy: molecular mechanisms of action.
Highly Cited
2012
Highly Cited
2012
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised…
Highly Cited
2011
Highly Cited
2011
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase…
Highly Cited
2010
Highly Cited
2010
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Highly Cited
2009
Highly Cited
2009
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
BACKGROUND Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in… 
Highly Cited
2006
Highly Cited
2006
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
BACKGROUND Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with… 
Highly Cited
2004
Highly Cited
2004
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer…
PURPOSE To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or… 
Highly Cited
2004
Highly Cited
2004
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
PURPOSE Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally active epidermal… 
Highly Cited
1989
Highly Cited
1989
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
A dosage formula has been derived from a retrospective analysis of carboplatin pharmacokinetics in 18 patients with pretreatment… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License